Skip to main content

Boundless Bio, Inc.

BOLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001782303

In the last 90 days, Boundless Bio, Inc. insiders filed 5 open-market purchases and 2 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $38.3M in total; no superinvestor holds it.

Holders of 5% or more of BOLD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Boundless Bio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BOLD
HolderLatest formStakeChangeFirst filedLatest filingFiling
Citadel Advisors LLC13G6.40%1.43M sharesNewDec 4, 20251 filingDec 4, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Boundless Bio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BOLD
Filed (ET)FilerFormStakeChangeEvent dateFiling
Dec 4, 20256:35 PM ETCitadel Advisors LLCand 6 others13G6.40%1.43M sharesNewNov 26, 2025SEC
Aug 14, 20255:57 PM ETRa Capital Management, L.P.and 3 others13G/A0.00%0 shares–Below 5%Jun 30, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Boundless Bio, Inc. shares.

No Form 144 notices for Boundless Bio, Inc. are on file.